N6-methyladenosine RNA methylation in diabetic kidney disease

Huang, Jiaan; Yang, Fan; Liu, Yan; Wang, Yuehua

doi:10.1016/j.biopha.2024.116185

Cited by 4 publications

(2 citation statements)

References 210 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…ALKBH5, a member of the alkB family, specifically obliterates m 6 A marks in the coding region and 3’UTR of single-stranded RNA, and directly eliminate methyl groups from m 6 A-methylated adenosine ( 26 ). These erasers contribute to the dynamic turnover of m 6 A modifications, influencing various cellular processes, including mRNA stability and translation efficiency, contributing to glucose metabolic disorders in multiple organs and tissues, such as the liver, kidney, and blood vessels ( 27 , 28 ).…”

Section: The Regulation Of Rna M 6 a Modificationmentioning

confidence: 99%

The m6A-ncRNAs axis in diabetes complications: novel mechanism and therapeutic potential

Yu,

Li,

et al. 2024

Front. Endocrinol.

View full text Add to dashboard Cite

Diabetes, a multifaceted metabolic disorder, poses a significant global health burden with its increasing prevalence and associated complications, such as diabetic nephropathy, diabetic retinopathy, diabetic cardiomyopathy, and diabetic angiopathy. Recent studies have highlighted the intricate interplay between N6-methyladenosine (m6A) and non-coding RNAs (ncRNAs) in key pathways implicated in these diabetes complications, like cell apoptosis, oxidative stress, and inflammation. Thus, understanding the mechanistic insights into how m6A dysregulation impacts the expression and function of ncRNAs opens new avenues for therapeutic interventions targeting the m6A-ncRNAs axis in diabetes complications. This review explores the regulatory roles of m6A modifications and ncRNAs, and stresses the role of the m6A-ncRNA axis in diabetes complications, providing a therapeutic potential for these diseases.

show abstract

Section: The Regulation Of Rna M 6 a Modificationmentioning

confidence: 99%

The m6A-ncRNAs axis in diabetes complications: novel mechanism and therapeutic potential

Yu,

Li,

et al. 2024

Front. Endocrinol.

View full text Add to dashboard Cite

show abstract

“…Diabetic kidney disease (DKD) is a prevalent and costly microvascular complication of diabetes ( 1 ). It has surpassed glomerulonephritis as the leading cause of chronic kidney disease (CKD) and end-stage renal disease (ESRD) ( 2 , 3 ).…”

Section: Introductionmentioning

confidence: 99%

Guild-level signature of gut microbiome for diabetic kidney disease

Tang,

Wu,

Liu

et al. 2024

mBio

View full text Add to dashboard Cite

Current microbiome signatures for chronic diseases such as diabetic kidney disease (DKD) are mainly based on low-resolution taxa such as genus or phyla and are often inconsistent among studies. In microbial ecosystems, bacterial functions are strain specific, and taxonomically different bacteria tend to form co-abundance functional groups called guilds. Here, we identified guild-level signatures for DKD by performing in-depth metagenomic sequencing and conducting genome-centric and guild-based analysis on fecal samples from 116 DKD patients and 91 healthy subjects. Redundancy analysis on 1,543 high-quality metagenome-assembled genomes (HQMAGs) identified 54 HQMAGs that were differentially distributed among the young healthy control group, elderly healthy control group, early-stage DKD patients (EDG), and late-stage DKD patients (LDG). Co-abundance network analysis classified the 54 HQMAGs into two guilds. Compared to guild 2, guild 1 contained more short-chain fatty acid biosynthesis genes and fewer genes encoding uremic toxin indole biosynthesis, antibiotic resistance, and virulence factors. Guild indices, derived from the total abundance of guild members and their diversity, delineated DKD patients from healthy subjects and between different severities of DKD. Age-adjusted partial Spearman correlation analysis showed that the guild indices were correlated with DKD disease progression and with risk indicators of poor prognosis. We further validated that the random forest classification model established with the 54 HQMAGs was also applicable for classifying patients with end-stage renal disease and healthy subjects in an independent data set. Therefore, this genome-level, guild-based microbial analysis strategy may identify DKD patients with different severity at an earlier stage to guide clinical interventions. IMPORTANCE Traditionally, microbiome research has been constrained by the reliance on taxonomic classifications that may not reflect the functional dynamics or the ecological interactions within microbial communities. By transcending these limitations with a genome-centric and guild-based analysis, our study sheds light on the intricate and specific interactions between microbial strains and diabetic kidney disease (DKD). We have unveiled two distinct microbial guilds with opposite influences on host health, which may redefine our understanding of microbial contributions to disease progression. The implications of our findings extend beyond mere association, providing potential pathways for intervention and opening new avenues for patient stratification in clinical settings. This work paves the way for a paradigm shift in microbiome research in DKD and potentially other chronic kidney diseases, from a focus on taxonomy to a more nuanced view of microbial ecology and function that is more closely aligned with clinical outcomes.

show abstract

A new perspective on targeting pulmonary arterial hypertension: Programmed cell death pathways (Autophagy, Pyroptosis, Ferroptosis)

Ge,

Zhang,

et al. 2024

Biomedicine & Pharmacotherapy

View full text Add to dashboard Cite

N6-methyladenosine RNA methylation in diabetic kidney disease

Cited by 4 publications

References 210 publications

The m6A-ncRNAs axis in diabetes complications: novel mechanism and therapeutic potential

The m6A-ncRNAs axis in diabetes complications: novel mechanism and therapeutic potential

Guild-level signature of gut microbiome for diabetic kidney disease

A new perspective on targeting pulmonary arterial hypertension: Programmed cell death pathways (Autophagy, Pyroptosis, Ferroptosis)

Contact Info

Product

Resources

About